Many traditional pharmacies are deciding not to carry FDA-approved GLP-1 drugs because they lose about $90 to $100 every time they dispense one, according to Scott Brunner, the chief executive for the Alliance for Pharmacy Compounding, an industry group
We prioritize patient safety, and our team carefully monitors for potential side effects, which are usually mild and temporary, such as nausea or diarrhea
Pharmacokinetic and pharmacodynamic effects of multiple-dose administration of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in obese participants with and without type 2 diabetes mellitus
Your provider will review your history before any infusion
Differences in product documentation, third-party testing visibility, and regulatory status can also vary between sellers